Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 9/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.35 |
| ▸ | HPGD | P15428 | 6/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205346 | 0.82 | TTR (0.46) | TTRNPC1RAB9AMAPTTDP1 | |
| SCHEMBL8498710 | 0.70 | TTR (0.69) | TTRNPSR1CYP2C9MAPTALDH1A1 | |
| SCHEMBL12578309 | 0.70 | BRD4 (0.42) | NPSR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL22158996 | 0.69 | TTR (0.62) | TTRNPC1MAPTALDH1A1DRD2 | |
| SCHEMBL18477953 | 0.69 | FDPS (0.54) | TTRNPSR1CYP2C9NPC1RAB9A | |
| SCHEMBL15445427 | 0.68 | TTR (0.69) | TTRNPSR1CYP2C9MAPTALDH1A1 | |
| SCHEMBL3623932 | 0.67 | ALDH1A1 (0.40) | NPSR1CYP2C9MAPTALDH1A1HPGD | |
| SCHEMBL7244289 | 0.67 | KCNA3 (0.62) | ALDH1A1L3MBTL1DRD2DRD4DRD3 | |
| SCHEMBL17917426 | 0.67 | ALDH1A1 (0.38) | CYP2C9NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL12577681 | 0.66 | MAOA (0.52) | NPC1RAB9AMAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2248812-B1 | FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8598226-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8492430-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | TTR 4602/4885NPSR1 85/4885CYP2C9 3201/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | TTR 4602/4885NPSR1 85/4885CYP2C9 3201/4885 |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | TTR 4602/4885NPSR1 85/4885CYP2C9 3201/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | TTR 4602/4885NPSR1 85/4885CYP2C9 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.